Douglas D Sheets, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 446 Nc 108 Hwy, Rutherfordton, NC 28139 Phone: 828-287-7383 Fax: 828-287-8020 |
David Clayton Billue, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 288 S Ridgecrest Ave Ste 1, Rutherfordton, NC 28139 Phone: 828-286-5583 Fax: 828-286-5584 |
News Archive
Today CLC bio Japan announced that they're expanding their Japanese outreach program in collaboration with RIKEN Omics Science Center to deliver free licenses for CLC Main Workbench to all academic organizations in the Tohoku earthquake and tsunami disaster area.
Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the worldwide launch of the SILS™ Stitch articulating suturing device for advanced laparoscopic surgery, including SILS single-incision procedures. The SILS Stitch instrument expands the Company's SILS product line, as well as its endoscopic suturing portfolio, which includes today's leading automated endosuturing product, the Endo Stitch™ instrument and reloads.
The unchecked activity of a cell signaling pathway crucial in embryonic development and the liver's response to injury leads to liver cancer, researchers from Duke University Medical Center and John Hopkins University School of Medicine have found.
According to research on fatty acids conducted at the universities of Helsinki and Tampere, the consumption of canola-type rapeseed oil decreases the level of fibrinogen detrimental to health in the body. The increased fibrinogen level, caused by an imbalance in essential fats in one's diet, decreases when saturated fatty acids are replaced with rapeseed oil.
MicroPhage, Inc. announced today that it has received two Qualifying Therapeutic Discovery Project (QTDP) grants totaling $977,916 from the IRS. The grants, awarded as part of the Affordable Care Act, apply to small-company R&D expenditures that reduce the cost and increase the quality of healthcare in the U.S. The grants will be applied to the development of MicroPhage's first product, the MRSA/MSSA Blood Culture Test, currently under review at the FDA.
› Verified 3 days ago